Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3214996 · 2 trials · 5 indications
Urinary Excretion of LY3214996 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered
| Arm | Type | Description |
|---|---|---|
| LY3214996 + [14C]-LY3214996 | EXPERIMENTAL | A single dose of LY3214996 and \[14C\]-LY3214996 administered orally. |
| LY3214996 Dose Escalation | EXPERIMENTAL | LY3214996 given orally once a day (or twice a day) for 21 days. |
| LY3214996 + Midazolam | EXPERIMENTAL | (Preliminary Drug-Drug Interactions \[DDI\]) LY3214996 given orally (once a day) and midazolam given orally on cycle 1 day 1 and cycle 1 day 16 (21 day cycles except cycle 1 only = 22 days). |
| LY3214996 Dose Expansion | EXPERIMENTAL | LY3214996 given orally (once a day) during each 21 day cycle. |
| LY3214996 + Abemaciclib | EXPERIMENTAL | Dose Escalation and Expansion- LY3214996 given orally (dose timing will be determined) and abemaciclib given orally (single dose given during lead in period) twice a day every 12 hours during 21 day cycle. |
| LY3214996 + Nab-Paclitaxel + Gemcitabine | EXPERIMENTAL | Dose Escalation and Expansion- LY3214996 given orally (dose timing will be determined) and nab-paclitaxel given intravenously (IV) on day 1, 8, and 15 and gemcitabine IV on day 1, 8, and 15 during each 28 day cycle. |
| LY3214996 + Encorafenib + Cetuximab | EXPERIMENTAL | Dose Escalation and Expansion- LY3214996 given orally, encorafenib given orally and cetuximab given IV. |
| Japan Part 1 | EXPERIMENTAL | LY3214996 given orally. |
| Japan Part 2 | EXPERIMENTAL | LY3214996 given orally and abemaciclib given orally. |
| Name | Type | Description |
|---|---|---|
| LY3214996 | DRUG | Administered orally |
| [14C]-LY3214996 | DRUG | Administered orally |
| Midazolam | DRUG | Administered orally |
| Abemaciclib | DRUG | Administered orally |
| Nab-paclitaxel | DRUG | Administered IV |
| Gemcitabine | DRUG | Administered IV |
| Encorafenib | DRUG | Administered orally |
| Cetuximab | DRUG | Administered IV |
Inclusion Criteria: * Overtly health males * Body mass index (BMI) of 18.0 to 32.0 kilograms per square meter (kg/m²), inclusive Exclusion Criteria: * Females * Male participants sexually active with a pregnant partner * Are currently enrolled in a clinical study or have participated, within the ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
LY3214996 is an investigational small molecule being studied for the treatment of advanced cancer, including metastatic melanoma, metastatic non-small cell lung cancer, and colorectal cancer. It has also been evaluated in healthy participants. The drug is in Phase 1 clinical development and is not yet approved by the FDA.
LY3214996 is a small molecule designed to target specific pathways involved in cancer cell growth. It is being studied in advanced and metastatic cancers, including melanoma, non-small cell lung cancer, and colorectal cancer. The drug is in Phase 1 clinical trials to evaluate its safety and efficacy.
LY3214996 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the NYSE under the ticker symbol LLY. The drug is currently in Phase 1 clinical development for advanced cancer and healthy participant studies.
LY3214996 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA. Clinical trials are ongoing or completed to evaluate its safety and potential efficacy in advanced cancer and healthy participants.
LY3214996 has been studied in two completed Phase 1 clinical trials. NCT02857270 evaluated the drug alone or in combination with other agents in participants with advanced or metastatic cancer, enrolling 210 participants. NCT04033341 studied the drug in healthy male participants, enrolling 6 participants.
LY3214996 is a unique investigational compound developed by Eli Lilly and Company. It is not known to be the same as any other marketed drug. It is being studied under its own name in clinical trials for advanced cancer and healthy participant studies.